[go: up one dir, main page]

MX2019011287A - Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados. - Google Patents

Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados.

Info

Publication number
MX2019011287A
MX2019011287A MX2019011287A MX2019011287A MX2019011287A MX 2019011287 A MX2019011287 A MX 2019011287A MX 2019011287 A MX2019011287 A MX 2019011287A MX 2019011287 A MX2019011287 A MX 2019011287A MX 2019011287 A MX2019011287 A MX 2019011287A
Authority
MX
Mexico
Prior art keywords
related disorders
therapeutic agent
phosphodiesterase inhibition
pharmaceutically acceptable
phosphodiesterase
Prior art date
Application number
MX2019011287A
Other languages
English (en)
Inventor
K Deshpande Supreet
A Kulkarni Sudhir
S Aslekar Atul
Original Assignee
Novalead Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novalead Pharma Inc filed Critical Novalead Pharma Inc
Publication of MX2019011287A publication Critical patent/MX2019011287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La composición farmacéutica para el tratamiento de trastornos relacionados con fosfodiesterasas comprende administrar a un sujeto una cantidad terapéuticamente efectiva de un compuesto de la Fórmula I o compuestos seleccionados del grupo conformado por Niclosamida, Oxiclozanida, Rafoxanida, Closantel, Dibromsalan, Metabromsalan, Tribromsalan, Nitazoxanida y sus profármacos, metabolitos, sales farmacéuticamente aceptables, solvatos y polimorfos en un portador, vehículo o diluyente farmacéuticamente aceptable.
MX2019011287A 2017-03-21 2018-03-14 Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados. MX2019011287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721009758 2017-03-21
PCT/IN2018/050140 WO2018173069A1 (en) 2017-03-21 2018-03-14 Therapeutic agent for phosphodiesterase inhibition and its related disorders

Publications (1)

Publication Number Publication Date
MX2019011287A true MX2019011287A (es) 2019-12-19

Family

ID=63585969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011287A MX2019011287A (es) 2017-03-21 2018-03-14 Agente terapéutico para la inhibición de fosfodiesterasas y sus trastornos relacionados.

Country Status (12)

Country Link
US (2) US11147779B2 (es)
EP (1) EP3601285A4 (es)
JP (1) JP7298928B2 (es)
KR (1) KR20190138647A (es)
CN (1) CN110650958A (es)
AU (1) AU2018238577B2 (es)
BR (1) BR112019019519A2 (es)
CA (1) CA3057284A1 (es)
MX (1) MX2019011287A (es)
PH (1) PH12019502176A1 (es)
WO (1) WO2018173069A1 (es)
ZA (1) ZA201906904B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
EA201890618A1 (ru) 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
WO2019241376A1 (en) * 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
GB201813876D0 (en) * 2018-08-24 2018-10-10 Antibiotx As Treatment
US20210369650A1 (en) * 2018-11-02 2021-12-02 UNION therapeutics A/S Treatment of inflammatory conditions
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
WO2021046446A1 (en) * 2019-09-06 2021-03-11 Yourchoice Therapeutics, Inc. Compositions and methods of use for enhancing fertility
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
MX2022012359A (es) * 2020-04-01 2022-10-21 Union Therapeutics As Formulacion.
KR20230020952A (ko) * 2020-04-01 2023-02-13 유니온 테라퓨틱스 에이/에스 치료
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
KR102594716B1 (ko) * 2020-04-17 2023-10-27 영남대학교 산학협력단 자가나노유화 약물전달시스템을 이용한 니클로사마이드 함유 경구 투여용 조성물 및 이의 제조방법
IL299274A (en) * 2020-06-23 2023-02-01 Pfizer A computerized support tool for decision-making and a medical device for detecting itching and predicting advanced itching attacks
GB202014160D0 (en) * 2020-09-09 2020-10-21 Nuchido Ltd Senolytic compounds and compositions
CN112294793B (zh) * 2020-10-21 2022-03-22 青岛海洋生物医药研究院股份有限公司 氯生太尔或其药学上可接受的盐在制备用于预防和/或治疗冠状病毒感染的药物中的应用
US11925611B2 (en) 2021-03-26 2024-03-12 United States Government As Represented By The Department Of Veterans Affairs Use of ZT-1A and analogs thereof to prevent and/or treat neurodegenerative and neurocognitive disorders
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN118994068A (zh) * 2023-05-19 2024-11-22 上海中医药大学 磷酸二酯酶4抑制剂、其药物组合物及其应用
US20250275992A1 (en) * 2024-03-04 2025-09-04 Ocusoft, Inc. Topical formulations for therapeutically active agents
CN119732761A (zh) * 2024-08-16 2025-04-01 首都医科大学附属北京口腔医院 一种治疗牙周病及预防牙釉质脱矿的隐形矫治器及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102782A3 (en) * 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
WO2004006906A2 (en) * 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
US8349817B2 (en) * 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
GB0711957D0 (en) * 2007-06-21 2007-08-01 Syntopix Ltd Formulations
WO2009032749A2 (en) * 2007-08-29 2009-03-12 The Regents Of The University Of Californina Salicylanilide modified peptides for use as oral therapeutics
WO2009089027A1 (en) * 2008-01-09 2009-07-16 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health Phosphodiesterase inhibitors
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
JP6307524B2 (ja) * 2013-02-04 2018-04-04 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｐｄｅ４阻害薬としての、４−アミノ置換縮合ピリミジン化合物
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
EP3967312A1 (en) * 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
EA201890618A1 (ru) * 2015-09-01 2018-10-31 Ферст Вэйв Байо, Инк. Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
SG11201808402RA (en) * 2016-04-11 2018-10-30 Genfit Methods of treatment for cholestatic and fibrotic diseases
CN107375280B (zh) * 2016-05-17 2021-03-05 中国科学院上海药物研究所 硝唑尼特及其药学上可接受的盐在制备用于治疗阿尔茨海默病的药物中的应用
CN107325067B (zh) * 2017-05-03 2020-05-12 广州中医药大学 磷酸二酯酶4抑制剂桑辛素m衍生物及其用途

Also Published As

Publication number Publication date
AU2018238577A1 (en) 2019-11-07
JP7298928B2 (ja) 2023-06-27
PH12019502176A1 (en) 2020-06-08
RU2019133323A3 (es) 2021-07-16
BR112019019519A2 (pt) 2020-04-22
ZA201906904B (en) 2020-09-30
KR20190138647A (ko) 2019-12-13
US11147779B2 (en) 2021-10-19
US20200022931A1 (en) 2020-01-23
WO2018173069A9 (en) 2018-11-01
AU2018238577B2 (en) 2023-02-02
JP2020511553A (ja) 2020-04-16
US20220000813A1 (en) 2022-01-06
WO2018173069A1 (en) 2018-09-27
EP3601285A1 (en) 2020-02-05
RU2019133323A (ru) 2021-04-21
CA3057284A1 (en) 2018-09-27
CN110650958A (zh) 2020-01-03
US11786492B2 (en) 2023-10-17
EP3601285A4 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
PH12019502176A1 (en) Therapeutic agent for phosphodiesterase inhibition and its related disorders
NZ777871A (en) Small molecule modulators of il-17
PL3976189T3 (pl) Nowe związki i ich kompozycje farmaceutyczne do leczenia chorób
MX2020007479A (es) Profármacos de ketamina, composiciones y usos de los mismos.
MX2020005363A (es) Compuestos heterociclicos como inhibidores de prmt5.
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
JO3724B1 (ar) تركيبات وطرق لعلاج اضطربات الجهاز العصبي المركزي (cns)
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
PH12014502173A1 (en) Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
MX2013012588A (es) Inhibidores de cinasa.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
NZ763816A (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
PH12021553248A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
ZA202006071B (en) Antiproliferation compounds and uses thereof
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2024015245A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas
MY201041A (en) Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2018005444A3 (en) Methods for treating cancer
MX2020008063A (es) Nuevos usos.